RxDoctor Payments Data

Patrick Koo, MD

Pulmonary Disease · Chattanooga, TNNPI 1982801866

Payments from drug & device makers

$11,232in general payments, 2019–2025

Across 35 payments — averaging $320.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • Inari Medical, Inc.$150
  • Covidien LP$139
  • Galvanize Therapeutics, Inc$130
  • Olympus America Inc.$115
  • Inspire Medical Systems, Inc.$113
  • plus $294 from 5 others

What the payments were for

  • Travel & lodging$1,20111%
  • Food & beverage$9508%
  • Education$9,08181%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,232 in reported general payments places this provider in the 70th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$86,558
Medicare patients
287
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$353,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter205$194,950
OpsumitMacitentan14$179,769
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr67$39,594
Spiriva HandihalerTiotropium Bromide34$37,485
Breo ElliptaFluticasone/Vilanterol60$29,119
Incruse ElliptaUmeclidinium Bromide44$22,527
SymbicortBudesonide/Formoterol Fumarate33$14,876
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$12,116
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$10,991
Formoterol Fumarate21$10,920
Spiriva RespimatTiotropium Bromide11$10,839
Albuterol Sulfate HfaAlbuterol Sulfate309$10,473
Arnuity ElliptaFluticasone Furoate29$10,297
Tiotropium Bromide11$7,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$67$179,76914 claims
AstraZenecaSymbicort, Breztri Aerosphere$103$25,86752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →